Attend the FiercePharmaMarketing Forum
This is a can't-miss event! Save 15% with promo code FPMF2018
Pfizer this week unveiled its $150 million expansion project in Michigan and is ready to hire about 200 employees.
Celgene has completed the first phase of a new manufacturing facility to produce the CAR-T drug candidate it is developing with partner Bluebird Bio.
The FDA has issued a warning letter to a Bayer finished products plant in Germany, where it says poor cleaning led to product cross-contamination.
A Merck manufacturing site in Ireland that was slated to close has been saved by the drugmaker’s hot-selling cancer drug Keytruda.
ImmunoGen will turn to contractors for its manufacturing needs, a move that will mean a small facility will close and 20 workers will be let go.
Novartis has started the clock ticking for some of the 450 employees at a Colorado plant which it is closing as part of its generics consolidation.
The impact of an FDA warning letter issued last month for a Celltrion plant in South Korea has broadened to Teva Pharmaceuticals.
AmerisourceBergen has received a grand jury subpoena to supply info to the DOJ about its testing of a syringe made at its PharMEDium lab in Tennessee.
Partner Therapeutics, a Boston operation which had its coming-out party a week ago, today announced it bought a drug from Sanofi.
An API maker in Bizen, Japan, has joined a growing list of Japanese drugmakers to be criticized by the FDA in warning letters and bans.